首页> 外文期刊>Nephron >Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome.
【24h】

Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome.

机译:肾病综合征患者中纤溶酶原激活物抑制剂1的表达增强。

获取原文
获取原文并翻译 | 示例
           

摘要

Hypercoagulability is present in patients with nephrotic syndrome. However, alterations in coagulation and fibrinolysis reflected in the glomeruli and urine are not fully understood. We examined plasma and urine concentrations of tissue-type plasminogen activator (tPA) and type 1 plasminogen activator inhibitor (PAI-1) in 33 patients with nephrotic syndrome (nephrotic group). We compared these concentrations with the concentrations in 30 nonnephrotic patients with chronic glomerulonephritis (nonnephrotic group) and with the concentrations in 30 healthy volunteers (control group). We also examined fibrin/fibrinogen degradation products in serum and urine and plasma D-dimers. The expression of tPA and PAI-1 was examined in isolated glomeruli using RT-PCR methods. Deposition of fibrinogen/fibrin-related antigen was observed by direct immunofluorescence. The incidence of fibrinogen/fibrin-related antigen deposition in the nephrotic group was significantly higher than that in the nonnephrotic group. The concentrations of fibrin/fibrinogen degradation products in serum and urine and of plasma D-dimers were significantly elevated in the nephrotic group as compared with the nonnephrotic and control groups. The plasma concentrations of tPA in the nephrotic group were significantly higher than those in the control group. The urinary excretion of tPA in the nephrotic group was also significantly higher than in the nonnephrotic and control groups. The urinary excretion of PAI-1 in the nephrotic group was higher than that in the control group. The ratio of PAI-1 mRNA to tPA mRNA in glomeruli was increased in the nephrotic group as compared with the nonnephrotic group. These results indicate that the fibrinolytic activity is increased in patients with nephrotic syndrome despite urinary losses of tPA. However, a relatively enhanced expression of PAI-1 may be involved in the intraglomerular fibrinogen/fibrin-related antigen deposition seen in nephrotic syndrome.
机译:肾病综合征患者存在高凝性。然而,尚未完全了解肾小球和尿液中凝血和纤维蛋白溶解的改变。我们检查了33名肾病综合征患者(肾病组)的血浆和尿液中组织型纤溶酶原激活物(tPA)和1型纤溶酶原激活物抑制剂(PAI-1)的浓度。我们将这些浓度与30例慢性肾小球肾炎非肾病患者的浓度(肾病组)和30例健康志愿者(对照组)的浓度进行了比较。我们还检查了血清,尿液和血浆D-二聚体中的纤维蛋白/纤维蛋白原降解产物。使用RT-PCR方法检测分离的肾小球中tPA和PAI-1的表达。通过直接免疫荧光观察到纤维蛋白原/纤维蛋白相关抗原的沉积。肾病组中纤维蛋白原/纤维蛋白相关抗原沉积的发生率显着高于非肾病组。与非肾病组和对照组相比,肾病组血清和尿液中纤维蛋白/纤维蛋白原降解产物的浓度以及血浆D-二聚体的浓度显着升高。肾病组的tPA血浆浓度显着高于对照组。肾病组中tPA的尿排泄也显着高于非肾病组和对照组。肾病组PAI-1的尿排泄量高于对照组。与非肾病组相比,肾病组肾小球中PAI-1 mRNA与tPA mRNA的比例增加。这些结果表明,尽管tPA尿流失,但肾病综合征患者的纤溶活性增加。但是,在肾病综合征中发现,PAI-1的表达相对增强可能参与了肾小球内纤维蛋白原/纤维蛋白相关抗原的沉积。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号